Tomoyoshi Soga

Prof. Tomoyoshi Soga

Institute for Advanced Biosciences, Keio University
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2003 in Journal of Proteome Research
Verified
Journal Article
Closed access
Tomoyoshi SogaTomoyoshi Soga
Tomoyoshi Soga
YOYoshiaki Ohashi
Yoshiaki Ohashi
YUYuki Ueno
Yuki Ueno
HNHisako Naraoka
Hisako Naraoka
MTMasaru Tomita
Masaru Tomita
TNTakaaki Nishioka
Takaaki Nishioka

1 June 2006 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Tomoyoshi SogaTomoyoshi Soga
Tomoyoshi Soga
RBRichard Baran
Richard Baran
Makoto SuematsuMakoto Suematsu
Makoto Suematsu
YUYuki Ueno
Yuki Ueno
SISatsuki Ikeda
Satsuki Ikeda
MTMasaru Tomita
Masaru Tomita
Metabolomics is an emerging tool that can be used to gain insights into cellular and physiological responses. Here we present a metabolome differential display method based on capillary electrophoresis time-of-flight mass spectrometry to profile liver metabolites following acetaminophen-induced hepatotoxicity. We globally detected 1,859 peaks in mouse liver extracts and highlighted multiple changes in metabolite levels, including an activation of the ophthalmate biosynthesis pathway. We confirmed that ophthalmate was synthesized from 2-aminobutyrate through consecutive reactions with γ-glutamylcysteine and glutathione synthetase. Changes in ophthalmate level in mouse serum and liver extracts were closely correlated and ophthalmate levels increased significantly in conjunction with glutathione consumption. Overall, our results provide a broad picture of hepatic metabolite changes following acetaminophen treatment. In addition, we specifically found that serum ophthalmate is a sensitive indicator of hepatic GSH depletion, and may be a new biomarker for oxidative stress. Our method can thus pinpoint specific metabolite changes and provide insights into the perturbation of metabolic pathways on a large scale and serve as a powerful new tool for discovering low molecular weight biomarkers.

17 April 2002 in Analytical Chemistry
Verified
Journal Article
Closed access
Tomoyoshi SogaTomoyoshi Soga
Tomoyoshi Soga
YUYuki Ueno
Yuki Ueno
HNHisako Naraoka
Hisako Naraoka
YOYoshiaki Ohashi
Yoshiaki Ohashi
MTMasaru Tomita
Masaru Tomita
TNTakaaki Nishioka
Takaaki Nishioka

6 October 2012 in Molecular Brain
Verified
Journal Article
Open access
PDF file
YIYoichi Imaizumi
Yoichi Imaizumi
YOYohei Okada
Yohei Okada
WAWado Akamatsu
Wado Akamatsu
MKMasato Koike
Masato Koike
NKNaoko Kuzumaki
Naoko Kuzumaki
Hideyuki OkanoHideyuki Okano
Hideyuki Okano
Background: Parkinson’s disease (PD) is a neurodegenerative disease characterized by selective degeneration of dopaminergic neurons in the substantia nigra (SN). The familial form of PD, PARK2, is caused by mutations in the parkin gene. parkin-knockout mouse models show some abnormalities, but they do not fully recapitulate the pathophysiology of human PARK2. Results: Here, we generated induced pluripotent stem cells (iPSCs) from two PARK2 patients. PARK2 iPSC-derived neurons showed increased oxidative stress and enhanced activity of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. iPSC-derived neurons, but not fibroblasts or iPSCs, exhibited abnormal mitochondrial morphology and impaired mitochondrial homeostasis. Although PARK2 patients rarely exhibit Lewy body (LB) formation with an accumulation of α-synuclein, α-synuclein accumulation was observed in the postmortem brain of one of the donor patients. This accumulation was also seen in the iPSC-derived neurons in the same patient. Conclusions: Thus, pathogenic changes in the brain of a PARK2 patient were recapitulated using iPSC technology. These novel findings reveal mechanistic insights into the onset of PARK2 and identify novel targets for drug screening and potential modified therapies for PD.

28 August 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KSKiyotoshi Satoh
Kiyotoshi Satoh
SYShinichi Yachida
Shinichi Yachida
Masahiro SugimotoMasahiro Sugimoto
Masahiro Sugimoto
MOMinoru Oshima
Minoru Oshima
TNToshitaka Nakagawa
Toshitaka Nakagawa
Tomoyoshi SogaTomoyoshi Soga
Tomoyoshi Soga
Cancer cells alter their metabolism for the production of precursors of macromolecules. However, the control mechanisms underlying this reprogramming are poorly understood. Here we show that metabolic reprogramming of colorectal cancer is caused chiefly by aberrant MYC expression. Multiomics-based analyses of paired normal and tumor tissues from 275 patients with colorectal cancer revealed that metabolic alterations occur at the adenoma stage of carcinogenesis, in a manner not associated with specific gene mutations involved in colorectal carcinogenesis. MYC expression induced at least 215 metabolic reactions by changing the expression levels of 121 metabolic genes and 39 transporter genes. Further, MYC negatively regulated the expression of genes involved in mitochondrial biogenesis and maintenance but positively regulated genes involved in DNA and histone methylation. Knockdown of MYC in colorectal cancer cells reset the altered metabolism and suppressed cell growth. Moreover, inhibition of MYC target pyrimidine synthesis genes such as CAD, UMPS, and CTPS blocked cell growth, and thus are potential targets for colorectal cancer therapy. Significance Metabolic reprogramming is one of the hallmarks of cancer. However, the underlying mechanisms that regulate cancer metabolism are poorly understood. Here we performed multiomics-based analysis of paired normal–tumor tissues from patients with colorectal cancer, which revealed that the protooncogene protein MYC regulated global metabolic reprogramming of colorectal cancer by modulating 215 metabolic reactions. Importantly, this metabolic reprogramming occurred in a manner not associated with specific gene mutations in colorectal carcinogenesis. For many years, small-molecule or biologic inhibitors of MYC have been required. Here we demonstrate that knockdown of MYC downstream pyrimidine synthesis genes contributes to the suppression of colorectal cancer cell proliferation similar to MYC, and thus pyrimidine synthesis pathways could be potential targets for colorectal cancer therapy.

12 June 2009 in Analytical Chemistry
Verified
Journal Article
Open access
Tomoyoshi SogaTomoyoshi Soga
Tomoyoshi Soga
KIKaori Igarashi
Kaori Igarashi
CIChiharu Ito
Chiharu Ito
KMKatsuo Mizobuchi
Katsuo Mizobuchi
HZHans-Peter Zimmermann
Hans-Peter Zimmermann
MTMasaru Tomita
Masaru Tomita
We describe a sheath flow capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS) method in the negative mode using a platinum electrospray ionization (ESI) spray needle, which allows the comprehensive analysis of anionic metabolites. The material of the spray needle had significant effect on the measurement of anions. A stainless steel spray needle was oxidized and corroded at the anodic electrode due to electrolysis. The precipitation of iron oxides (rust) plugged the capillary outlet, resulting in shortened capillary lifetime. Many anionic metabolites also formed complexes with the iron oxides or migrating nickel ion, which was also generated by electrolysis and moved toward the cathode (the capillary inlet). The metal−anion complex formation significantly reduced detection sensitivity of the anionic compounds. The use of a platinum ESI needle prevented both oxidation of the metals and needle corrosion. Sensitivity using the platinum needle increased from several- to 63-fold, with the largest improvements for anions exhibiting high metal chelating properties such as carboxylic acids, nucleotides, and coenzyme A compounds. The detection limits for most anions were between 0.03 and 0.87 μmol/L (0.8 and 24 fmol) at a signal-to-noise ratio of 3. This method is quantitative, sensitive, and robust, and its utility was demonstrated by the analysis of the metabolites in the central metabolic pathways extracted from mouse liver.